Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance
Author Information
Author(s): Kekeeva Tatiana, Dudina Irina, Andreeva Yulia, Tanas Alexander, Kalinkin Alexey, Musatova Victoria, Chernorubashkina Natalia, Khokhlova Svetlana, Tikhomirova Tatiana, Volkonsky Mikhail, Kutsev Sergey, Zaletaev Dmitry, Strelnikov Vladimir, Szafron Lukasz
Primary Institution: Laboratory of Epigenetics, Research Centre for Medical Genetics, Moscow, Russia
Hypothesis
To investigate the heterogeneity of the HRD-positive HGSOC.
Conclusion
The Meth+ subgroup had poor outcomes in terms of chemotherapy response, olaparib benefit, and progression-free survival compared to the other HRD+ subgroups.
Supporting Evidence
- HRD-positive status was detected in 65% of samples.
- The BRCA+ group showed the best outcome in platinum therapy with an ORR of 96%.
- The Meth+ subgroup had a median PFS of 19 months, significantly lower than the BRCA+ group's 46 months.
- Patients with Meth+ HGSOC showed a significantly lower ORR to platinum therapy at 84%.
Takeaway
This study looked at different types of ovarian cancer that have a specific problem with DNA repair and found that some types respond better to treatment than others.
Methodology
The study evaluated HRD status, including BRCA mutations and methylation status, in 352 HGSOC specimens and divided them into three molecular subgroups.
Limitations
The study may not account for all potential factors influencing outcomes in HRD-positive patients.
Participant Demographics
Patients were women aged 18 years or older with histologically confirmed high-grade serous ovarian cancer.
Statistical Information
P-Value
0.006
Confidence Interval
95% CI [21–40]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website